Business

Sunovion Pharmaceuticals has announced that it will sell "certain rights" to its Xopenex levalbuterol inhalation solution to Akorn for $45 million. Rights to the Xopenex HFA MDI are being retained by Sunovion. Akorn says that it will begin shipping the inhalation solution as soon as the deal is closed. Akorn CEO Raj Rai said, "We are excited to announce this … [Read more...] about Akorn acquires Sunovion’s Xopenex inhalation solution

Acorda Therapeutics has announced that it will acquire inhaled drug developer Civitas Therapeutics, including rights to the ARCUS inhalation platform, for $525 million in cash. The deal includes worldwide rights to Civitas's lead candidate, CVT-301 inhaled L-dopa for the treatment of OFF episodes in Parkinson’s disease patients. Civitas CEO Mark Iwicki said, “We … [Read more...] about Civitas Therapeutics to be acquired by Acorda

Dr. Reddy’s Laboratories have announced that the company has launched generic levalbuterol inhalation solution in the US as of September 23, 2014. The generic version of Sunovion's Xopenex is available in 0.31 mg /3 mL, 0.63 mg /3 mL, and 1.25 mg / 3 mL unit dose vials. Read the Dr. Reddy's press release. … [Read more...] about Dr. Reddy’s launches generic Xopenex inhalation solution in the US

Almac subsidiary Galen Ltd will pay Medical Developments International (MVP) approximately A$650,000 (~US$587,000) up front for a license to market and distribute MVP's Penthrox inhaled methoxyflurane in the UK and Ireland. The deal also includes undisclosed regulatory and sales milestone payments. Penthrox, a non-opioid analgesic delivered via a proprietary vapor … [Read more...] about Galen to market Penthrox inhaled methoxyflurane in the UK and Ireland

In its most recent interim report, Verona Pharma says that it raised over £14 million pounds earlier this year which will allow it to continue development of its RPL554, an inhaled PDE3/PDE4 inhibitor, for the treatment of asthma and COPD. The company says that it is developing a new "commercially scalable" nebulized formulation of the drug. Previous testing has … [Read more...] about Verona says that it can fund studies of RPL554 up to Phase 2b

Prosonix has announced that a consortium of inhaled medicine and respiratory disease researchers with funding from the Biomedical Catalyst "has confirmed the potential of its Multi-component Particle (MCP) Technology for creating novel inhaled, dual and triple fixed dose combination (FDC) therapies for respiratory diseases." The research project included in vitro … [Read more...] about Study shows potential of Prosonix multi-component particle technology

Cipla has announced that it has entered into a distribution agreement with S&D Pharma in the Czech Republic and Slovakia in which S&D will distribute Cipla products. The deal includes distribution "in the near future, once the necessary regulatory and reimbursement approvals are in place," of two dosages of salmeterol/fluticasone, 25/125 mcg and 25/250 mcg, with the … [Read more...] about Cipla to launch salmeterol/fluticasone MDI in Czech Republic, Slovakia

Pfizer UK has announced that it has signed an exclusive agreement with Novartis to market the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in the UK for the treatment of COPD. Seebri Breezhaler was approved in Europe in October 2012 and has been available in the UK since November of that year. Ultibro Breezhaler … [Read more...] about Pfizer to market Ultibro Breezhaler and Seebri Breezhaler in the UK